BR112014002121A2 - modelo de câncer de mama de animal knock-in não humano pik3ca h1047r - Google Patents

modelo de câncer de mama de animal knock-in não humano pik3ca h1047r

Info

Publication number
BR112014002121A2
BR112014002121A2 BR112014002121A BR112014002121A BR112014002121A2 BR 112014002121 A2 BR112014002121 A2 BR 112014002121A2 BR 112014002121 A BR112014002121 A BR 112014002121A BR 112014002121 A BR112014002121 A BR 112014002121A BR 112014002121 A2 BR112014002121 A2 BR 112014002121A2
Authority
BR
Brazil
Prior art keywords
breast cancer
pik3ca
knock
model
cancer model
Prior art date
Application number
BR112014002121A
Other languages
English (en)
Inventor
Seshagiri Somasekar
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112014002121A2 publication Critical patent/BR112014002121A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/20—Animal model comprising regulated expression system
    • A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C12N2015/8572—Animal models for proliferative diseases, e.g. comprising an oncogene

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plant Pathology (AREA)

Abstract

abstract of the disclosure the invention concerns the development of a pik3ca h1047r knock-in non-human animal breast cancer model, and its use for identification of a spontaneous loss-of-function tp53 mutation involved in spindle cell tumor formation. the invention further concerns the identification of additional somatic mutations and copy number aberrations in the breast tumors using this model, and methods and means for the diagnosis and treatment of breast cancer. ___________________________________________________________________________________ tradução do resumo resumo patente de invenção: "modelo de câncer de mama de animal knock-in não humano pik3ca h1047r". a invenção envolve o desenvolvimento de um modelo de câncer de mama animal não humano knock-in pik3ca h1047r e seu uso para identificação de uma mutação tp53 de perda de função espontânea envolvida na formação de tumor de célula fusiforme. a invenção ainda envolve a identificação de mutações somáticas adicionais e aberrações de número de cópia nos tumores de mama usando este modelo e métodos e meios para o diagnóstico e tratamento de câncer de mama.
BR112014002121A 2011-07-28 2012-07-26 modelo de câncer de mama de animal knock-in não humano pik3ca h1047r BR112014002121A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161574161P 2011-07-28 2011-07-28
PCT/US2012/000336 WO2013015833A2 (en) 2011-07-28 2012-07-26 Pik3ca h1047r knock-in non-human animal breast cancer model

Publications (1)

Publication Number Publication Date
BR112014002121A2 true BR112014002121A2 (pt) 2017-02-21

Family

ID=46690680

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014002121A BR112014002121A2 (pt) 2011-07-28 2012-07-26 modelo de câncer de mama de animal knock-in não humano pik3ca h1047r

Country Status (10)

Country Link
US (1) US20140298493A1 (pt)
EP (1) EP2736325B1 (pt)
JP (1) JP2014529298A (pt)
KR (1) KR20140050689A (pt)
CN (1) CN104010494B (pt)
BR (1) BR112014002121A2 (pt)
CA (1) CA2843222A1 (pt)
MX (1) MX2014001063A (pt)
RU (1) RU2014107713A (pt)
WO (1) WO2013015833A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6078383B2 (ja) * 2013-03-07 2017-02-08 学校法人順正学園 トランスジェニック非ヒト哺乳動物
EP3842554B1 (en) * 2014-05-09 2022-12-14 Memorial Sloan Kettering Cancer Center Biomarkers for response to pi3k inhibitors
CA2985894A1 (en) * 2015-05-15 2016-11-24 Memorial Sloan-Kettering Cancer Center Use of phosphoinositide 3-kinase inhibitors for treatment of vascular malformations
JP2018531606A (ja) * 2015-10-30 2018-11-01 ザ ジャクソン ラボラトリーＴｈｅ Ｊａｃｋｓｏｎ Ｌａｂｏｒａｔｏｒｙ 腫瘍分析に関する組成物及び方法
RU2608960C1 (ru) * 2016-03-18 2017-01-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "РОНЦ им. Н.Н. Блохина" Минздрава России) Клеточная линия crov Cel муцинозного рака яичников человека, предназначенная для разработки лечения таргетными препаратами
CN107828786A (zh) * 2017-10-24 2018-03-23 昆明理工大学 靶向敲除PIK3CA基因的sgRNA及应用
BR112021015353A2 (pt) 2019-02-06 2021-10-05 Venthera, Inc. Inibidores de fosfoinositídeo 3-cinase tópicos
KR102191341B1 (ko) 2019-03-15 2020-12-16 국립암센터 유방암 동물모델의 제조방법 및 이의 용도

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
PL3296407T3 (pl) * 2004-03-02 2019-11-29 Univ Johns Hopkins Mutacje genu pik3ca w nowotworach ludzkich
EP2041139B1 (en) 2006-04-26 2011-11-09 F. Hoffmann-La Roche AG Pharmaceutical compounds
EP1978106A1 (en) * 2007-04-07 2008-10-08 Universitätsklinikum Hamburg-Eppendorf Detection of ESR1 amplification in endometrium cancer and ovary cancer
JP2010523670A (ja) * 2007-04-10 2010-07-15 エクセリクシス， インク． Ｐｉ３ｋアルファのピリドピリミジノン阻害剤を使用した治療方法
MX2010006039A (es) * 2007-12-03 2010-06-23 Enzon Pharmaceuticals Inc Compuestos antagonistas del acido ribonucleico para la modulacion de la expresion de la fosfoinositida-3-cinasa catalitica.
EP2279188B1 (en) * 2008-05-30 2015-01-28 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
CN101445832B (zh) * 2008-12-23 2011-09-14 广州益善生物技术有限公司 Pik3ca基因突变的检测探针、液相芯片及其检测方法
WO2011031861A1 (en) * 2009-09-09 2011-03-17 Quintiles Transnational Corp. Methods for predicting responsiveness of a disease or disorder to a receptor tyrosine kinase inhibitor by analysis of mutations in pik3ca
WO2011060380A1 (en) * 2009-11-14 2011-05-19 The Regents Of The University Of California Pik3ca mutation status and sash1 expression predicts synergy between lapatinib and an akt inhibitor in her2 positive breast cancer
EP2510121A1 (en) * 2009-12-11 2012-10-17 Wyeth LLC Phosphatidylinositol-3-kinase pathway biomarkers
EP2524231B1 (en) * 2010-01-13 2017-06-28 Wyeth LLC A CUT-POINT IN PTEN PROTEIN EXPRESSION THAT ACCURATELY IDENTIFIES TUMORS AND IS PREDICTIVE OF DRUG RESPONSE TO A PAN-ErbB INHIBITOR

Also Published As

Publication number Publication date
MX2014001063A (es) 2014-09-01
CA2843222A1 (en) 2013-01-31
WO2013015833A2 (en) 2013-01-31
CN104010494B (zh) 2017-07-04
EP2736325A2 (en) 2014-06-04
WO2013015833A3 (en) 2013-09-26
RU2014107713A (ru) 2015-09-10
EP2736325B1 (en) 2018-10-10
KR20140050689A (ko) 2014-04-29
JP2014529298A (ja) 2014-11-06
US20140298493A1 (en) 2014-10-02
CN104010494A (zh) 2014-08-27

Similar Documents

Publication Publication Date Title
BR112014002121A2 (pt) modelo de câncer de mama de animal knock-in não humano pik3ca h1047r
MX2014005800A (es) Mutaciones del receptor notch humano y su uso.
MX2019013117A (es) Moleculas de union al dominio de fibronectina de tipo iii del receptor del factor de crecimiento epidermico y del receptor del factor de crecimiento de hepatocitos (egfr y c-met).
MX2016013832A (es) Composiciones y metodos para tratar hemoglobinopatias.
BR112013023050A2 (pt) “antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal”
BR112016002385A2 (pt) animal não humano, célula, tecido ou embrião, vetor de alvejamento, constructo de vetor de alvejamento, e, métodos para produzir um animal não humano e para modificar um lócus de incrna em uma célula pluripotente
IL280962A (en) Methods for delivering gene editing reagents to cells within organs
CL2017000382A1 (es) Compuestos bicíclicos sustituidos
WO2008099280A3 (en) Regulation of expression of pi3kb protein in tumors
SI2970878T1 (sl) Postopki in reagenti za vzdrževanje preživetja rakavih celic v kirurško odstranjenem tkivu
EA201591859A1 (ru) Фармацевтическая композиция, содержащая гиалуроновую кислоту, для использования при лечении болезни черного диска
EP2588631A4 (en) GENETIC MUTATION OF CK2 PROTEIN KINASE, AMPLIFICATIONS AND POLYMORPHISMS IN HUMAN CANCER, AND METHODS OF USE
Zabrocka et al. Simultaneous occurrence of non‑Hodgkin lymphoma, renal cell carcinoma and oncocytoma: A case report
Liao et al. The expression of MIR-221 and MIR-222 in non-small cell lung cancer and their significances
Han et al. Correlation of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer
Yanduan et al. Autophagy induced by low-intensity ultrasound combined with microbubbles in human prostate cancer cells PC3 cells and DU145 cells
Qiao et al. The expression and clinical significance of TAK1 in esophageal cancer
Walkley Modeling osteosarcoma: in vitro and in vivo approaches
Obeidat et al. Pituicytoma: A case Report
Hadžisejdić et al. Expression of metalloproteinase 2 and 9 in prostate carcinoma at the positive margin of radical prostatectomy specimens
Gong et al. The response evaluation and predictive value of Ki67 expression in neoadjuvant chemotherapy for breast cancer
Li et al. The correlation between RhoA and C-myc expression and the development of gastric cancer
김진백 Efficient Procurement Auction Process for Supply Chain Formation
Liu et al. Relationship between the expression of MMP-9, MMP-13, HIF-1α and clinical pathologic features, EGFR mutation and prognosis in lung adenocarcinoma
Song et al. Research progress on expression as well as clinical significance of Gastrin and Reg gene in gastric cancer tissue

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]